Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antineoplastic drugs

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Antineoplastic drugs. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-002071-34 Sponsor Protocol Number: ALLOCATE Start Date*: 2019-10-31
    Sponsor Name:Vejle Hospital
    Full Title: Allocation of patients with pre-treated solid tumors to anti-cancer therapy based on gene expression drug response prediction - a phase II basket trial
    Medical condition: Breast cancer Ovarian cancer Lung cancer Colorectal cancer Prostate cancer Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    20.1 100000004864 10080083 Advanced lung cancer LLT
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    20.0 100000004864 10036910 Prostate cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006330-16 Sponsor Protocol Number: IRFMN-MPM-6077 Start Date*: 2013-05-23
    Sponsor Name:Istituto di ricerche farmacologiche "Mario Negri"
    Full Title: ATREUS TRIAL A PHASE II STUDY ON THE ACTIVITY OF TRABECTEDIN IN PRETREATED EPITHELIOID OR BIPHASIC/SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Medical condition: Malignant Pleural Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004126-56 Sponsor Protocol Number: NUTH-2005-03523 Start Date*: 2006-03-07
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust
    Full Title: Observational pharmacokinetic study of doxorubicin and cyclophosphamide in patients with early breast cancer.
    Medical condition: Early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-005019-34 Sponsor Protocol Number: CTMT212X2106 Start Date*: 2016-05-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors
    Medical condition: Solid tumors, Pancreatic Cancer, Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009461-33 Sponsor Protocol Number: AV-IT-001 Start Date*: 2009-06-04
    Sponsor Name:AISAR ASSOCIAZIONE ITALIANA PER LO STUDIO DEGLI ANTIMICROBICI E DELLE RESISTENZE
    Full Title: A Phase IIa, Open-Label, Dose-Escalating Study to Evaluate the Safety of AV-951 in Combination with Everolimus in Subjects with Metastatic Renal Cell Carcinoma
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002406-37 Sponsor Protocol Number: 170 Start Date*: 2016-02-24
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc
    Full Title: A Phase 2 Study of Pembrolizumab (MK 3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)
    Medical condition: relapsed or refractory Primary Mediastinal Large B-Cell Lymphoma or Relapsed or Refractory Richter Syndrome (rrRS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036710 Primary mediastinal large B-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) PL (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004859-31 Sponsor Protocol Number: UNITO-EMN10 Start Date*: 2015-04-20
    Sponsor Name:Dipartimento di Biotecnologie Molecolari e Scienze per la Salute Università degli Studi di Torino
    Full Title: A MULTIARM, OPEN LABEL, RANDOMIZED PHASE II STUDY OF MLN9708 PLUS ORAL DEXAMETHASONE or PLUS ORAL CYCLOPHOSPHAMIDE AND DEXAMETHASONE or PLUS BENDAMUSTINE AND DEXAMETHASONE or PLUS ORAL THALIDOMIDE...
    Medical condition: Patients aged ≥ 65 years or younger not eligible for transplantation affected by newly diagnosed Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003993-24 Sponsor Protocol Number: CA186006 Start Date*: 2008-05-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage IV Melanoma. Revised Protocol 0...
    Medical condition: MELANOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025670 Malignant melanoma stage III LLT
    9.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005241-45 Sponsor Protocol Number: MK3475-061 Start Date*: 2015-04-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after Fi...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) EE (Completed) ES (Completed) IE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004482-14 Sponsor Protocol Number: CEGF816X2101 Start Date*: 2014-08-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II, multicenter, open-label study of EGFRmut–TKI EGF816,administered orally in adult patients with EGFRmut solid malignancies
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Temporarily Halted) FR (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000972-88 Sponsor Protocol Number: MK3475-062 Start Date*: 2015-08-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cispla...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) LV (Completed) NL (Completed) ES (Completed) CZ (Completed) FR (Completed) AT (Completed) HU (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002089-37 Sponsor Protocol Number: EMN18 Start Date*: 2019-03-04
    Sponsor Name:EUROPEAN MYELOMA NETWORK
    Full Title: A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II STUDY COMPARING DARATUMUMAB combined with BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE (Dara-VCd) VERSUS THE ASSOCIATION OF BORTEZOMIB-THALIDOMIDE-DEXAME...
    Medical condition: YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIGIBLE TO THE AUTOLOGOUS TRANSMISSION OF STEM CELLS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002320-29 Sponsor Protocol Number: XL184-301 Start Date*: 2009-01-23
    Sponsor Name:Exelixis, Inc.
    Full Title: Estudio internacional, aleatorizado, doble ciego, de fase 3 para evaluar la eficacia de XL184 frente a placebo en pacientes con cáncer medular tiroideo, no extirpable, localmente avanzado o metast...
    Medical condition: Cáncer medular tiroideo Medullary thyroid carcinoma (MTC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055107 Thyroid cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) SE (Completed) FR (Completed) GB (Completed) DK (Completed) BE (Completed) DE (Completed) IT (Completed) AT (Completed) PT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002109-38 Sponsor Protocol Number: AV-951-08-104 Start Date*: Information not available in EudraCT
    Sponsor Name:AVEO Pharmaceuticals, Inc.
    Full Title: A Phase 1b/2a, Open-Label, Multi-Center Study of AV-951 in Combination with Paclitaxel in Subjects with Advanced or Metastatic Breast Cancer
    Medical condition: Advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002834-35 Sponsor Protocol Number: PARERE Start Date*: 2020-09-24
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients.
    Medical condition: RAS and BRAF wild-type chemorefractory metastatic colorectal cancer patients
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004795-39 Sponsor Protocol Number: LSO-OL005 Start Date*: 2008-06-12
    Sponsor Name:Light Sciences Oncology Inc.
    Full Title: A Phase III Randomised Study to Evaluate Survival of Patients Treated with Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LED) as Compared to the Standard of Care Therapies in the...
    Medical condition: Patients with unresectable hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) SE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001550-29 Sponsor Protocol Number: AXI-IIG-02 Start Date*: 2011-08-11
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos
    Full Title: A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pa...
    Medical condition: Patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancreatic origin (carcinoids)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000722-54 Sponsor Protocol Number: MDV3100-10(C3431013) Start Date*: 2013-10-17
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Can...
    Medical condition: Patients With Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FI (Completed) DE (Ongoing) SK (Completed) BE (Completed) SE (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-001202-42 Sponsor Protocol Number: D419QC00002 Start Date*: 2016-11-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients with Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
    Medical condition: Patients with extensive-stage small-cell lung cancer (ED-SCLC) who have refractory or resistant disease from prior platinum-based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004414-35 Sponsor Protocol Number: IMPRESSNorway Start Date*: 2021-02-19
    Sponsor Name:Oslo University Hospital
    Full Title: Improving public cancer care by implementing precision medicine in Norway
    Medical condition: Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 11:50:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA